Cargando…
Post-COVID-19 syndrome and quality of life impairment in severe COVID-19 Mexican patients
INTRODUCTION: Post-COVID-19 syndrome (PCS) usually occurs 3 months after the onset of COVID-19 with a symptom duration of at least 2 months without an alternative diagnosis. OBJECTIVE: This study aimed to describe the prevalence, characteristics, and impact on the quality of life (QoL) of post-COVID...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225709/ https://www.ncbi.nlm.nih.gov/pubmed/37255755 http://dx.doi.org/10.3389/fpubh.2023.1155951 |
_version_ | 1785050434676719616 |
---|---|
author | Román-Montes, Carla Marina Flores-Soto, Yesenia Guaracha-Basañez, Guillermo Arturo Tamez-Torres, Karla María Sifuentes-Osornio, José González-Lara, Ma. Fernanda de León, Alfredo Ponce |
author_facet | Román-Montes, Carla Marina Flores-Soto, Yesenia Guaracha-Basañez, Guillermo Arturo Tamez-Torres, Karla María Sifuentes-Osornio, José González-Lara, Ma. Fernanda de León, Alfredo Ponce |
author_sort | Román-Montes, Carla Marina |
collection | PubMed |
description | INTRODUCTION: Post-COVID-19 syndrome (PCS) usually occurs 3 months after the onset of COVID-19 with a symptom duration of at least 2 months without an alternative diagnosis. OBJECTIVE: This study aimed to describe the prevalence, characteristics, and impact on the quality of life (QoL) of post-COVID-19 syndrome in patients with a history of hospitalization for COVID-19. MATERIALS AND METHODS: We conducted a cross-sectional study. Patients who required hospitalization due to COVID-19 between March 2020 and October 2021 were invited to answer a PCS questionnaire and the EQ-5D instrument. A total of 246 patients were included: 187 (76%) met the definition of PCS and 54% were men, with a median age of 50 years (IQR 41–63). RESULTS: From 187 patients with PCS, the median time to symptom onset after hospital discharge was 1 day (IQR 1–20), and the median symptom duration was 150 days (IQR 90–225). A total of 27 different symptoms were reported; the most frequent were difficulty concentrating (81%), dyspnea (75%), arthralgia (71%), fatigue (68%), and hair loss (60%). Some symptoms, such as difficulty concentrating, arthralgia/myalgia, and hair loss, were more prevalent in women with PCS. Patients with PCS had a higher frequency of tobacco smoking (37 vs. 4%, p = 0.02) and increased severity of lung involvement in the initial chest tomography (75 vs. 58%, p = 0.01) than those without PCS. Patients with PCS were less likely to receive antivirals (15.5 vs. 27%, p = 0.04). No difference between ICU admission, mechanical ventilation, and length of hospital stay was found. Patients with PCS had a lower visual analog scale result for EQ-5D vs. those without (80 [IQR 70–90] vs. 89.5 [IQR 75–90], p = 0.05). All five QoL dimensions were affected in PCS patients, showing increased pain/discomfort (67 vs. 39%, p = < 0.001), difficulties in performing usual activities (39.2 vs. 20.3%, p = 0.03), and anxiety/depression (57.5 vs. 37%, p = 0.02). CONCLUSION: PCS occurred in 76% of hospitalized patients with prolonged duration and QoL impairment. Neurological symptoms such as difficulty concentrating were the most frequent symptoms. Timely diagnostic and therapeutic interventions are required. |
format | Online Article Text |
id | pubmed-10225709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102257092023-05-30 Post-COVID-19 syndrome and quality of life impairment in severe COVID-19 Mexican patients Román-Montes, Carla Marina Flores-Soto, Yesenia Guaracha-Basañez, Guillermo Arturo Tamez-Torres, Karla María Sifuentes-Osornio, José González-Lara, Ma. Fernanda de León, Alfredo Ponce Front Public Health Public Health INTRODUCTION: Post-COVID-19 syndrome (PCS) usually occurs 3 months after the onset of COVID-19 with a symptom duration of at least 2 months without an alternative diagnosis. OBJECTIVE: This study aimed to describe the prevalence, characteristics, and impact on the quality of life (QoL) of post-COVID-19 syndrome in patients with a history of hospitalization for COVID-19. MATERIALS AND METHODS: We conducted a cross-sectional study. Patients who required hospitalization due to COVID-19 between March 2020 and October 2021 were invited to answer a PCS questionnaire and the EQ-5D instrument. A total of 246 patients were included: 187 (76%) met the definition of PCS and 54% were men, with a median age of 50 years (IQR 41–63). RESULTS: From 187 patients with PCS, the median time to symptom onset after hospital discharge was 1 day (IQR 1–20), and the median symptom duration was 150 days (IQR 90–225). A total of 27 different symptoms were reported; the most frequent were difficulty concentrating (81%), dyspnea (75%), arthralgia (71%), fatigue (68%), and hair loss (60%). Some symptoms, such as difficulty concentrating, arthralgia/myalgia, and hair loss, were more prevalent in women with PCS. Patients with PCS had a higher frequency of tobacco smoking (37 vs. 4%, p = 0.02) and increased severity of lung involvement in the initial chest tomography (75 vs. 58%, p = 0.01) than those without PCS. Patients with PCS were less likely to receive antivirals (15.5 vs. 27%, p = 0.04). No difference between ICU admission, mechanical ventilation, and length of hospital stay was found. Patients with PCS had a lower visual analog scale result for EQ-5D vs. those without (80 [IQR 70–90] vs. 89.5 [IQR 75–90], p = 0.05). All five QoL dimensions were affected in PCS patients, showing increased pain/discomfort (67 vs. 39%, p = < 0.001), difficulties in performing usual activities (39.2 vs. 20.3%, p = 0.03), and anxiety/depression (57.5 vs. 37%, p = 0.02). CONCLUSION: PCS occurred in 76% of hospitalized patients with prolonged duration and QoL impairment. Neurological symptoms such as difficulty concentrating were the most frequent symptoms. Timely diagnostic and therapeutic interventions are required. Frontiers Media S.A. 2023-05-15 /pmc/articles/PMC10225709/ /pubmed/37255755 http://dx.doi.org/10.3389/fpubh.2023.1155951 Text en Copyright © 2023 Román-Montes, Flores-Soto, Guaracha-Basañez, Tamez-Torres, Sifuentes-Osornio, González-Lara and León. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Román-Montes, Carla Marina Flores-Soto, Yesenia Guaracha-Basañez, Guillermo Arturo Tamez-Torres, Karla María Sifuentes-Osornio, José González-Lara, Ma. Fernanda de León, Alfredo Ponce Post-COVID-19 syndrome and quality of life impairment in severe COVID-19 Mexican patients |
title | Post-COVID-19 syndrome and quality of life impairment in severe COVID-19 Mexican patients |
title_full | Post-COVID-19 syndrome and quality of life impairment in severe COVID-19 Mexican patients |
title_fullStr | Post-COVID-19 syndrome and quality of life impairment in severe COVID-19 Mexican patients |
title_full_unstemmed | Post-COVID-19 syndrome and quality of life impairment in severe COVID-19 Mexican patients |
title_short | Post-COVID-19 syndrome and quality of life impairment in severe COVID-19 Mexican patients |
title_sort | post-covid-19 syndrome and quality of life impairment in severe covid-19 mexican patients |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225709/ https://www.ncbi.nlm.nih.gov/pubmed/37255755 http://dx.doi.org/10.3389/fpubh.2023.1155951 |
work_keys_str_mv | AT romanmontescarlamarina postcovid19syndromeandqualityoflifeimpairmentinseverecovid19mexicanpatients AT floressotoyesenia postcovid19syndromeandqualityoflifeimpairmentinseverecovid19mexicanpatients AT guarachabasanezguillermoarturo postcovid19syndromeandqualityoflifeimpairmentinseverecovid19mexicanpatients AT tameztorreskarlamaria postcovid19syndromeandqualityoflifeimpairmentinseverecovid19mexicanpatients AT sifuentesosorniojose postcovid19syndromeandqualityoflifeimpairmentinseverecovid19mexicanpatients AT gonzalezlaramafernanda postcovid19syndromeandqualityoflifeimpairmentinseverecovid19mexicanpatients AT deleonalfredoponce postcovid19syndromeandqualityoflifeimpairmentinseverecovid19mexicanpatients |